Catalent (CTLT) FQ4 results: Revenues: $725.7M (+5.9%); Softgel Technologies: $244.7M (+1.5%); Biologics and Specialty Drug Delivery: $231.1M (+18.2%); Oral Drug Delivery: $174.1M (+13.3%); Clinical Supply Services: $85.1M (-20.9%).
Net Income: $71.1M (-14.0%); Non-GAAP Net Income: $102.9M (+14.3%); EPS: $0.44 (-27.9%); Non-GAAP EPS: $0.70 (+4.5%); CF Ops: $247.7M (-33.9%).
FY 2020 guidance: Revenue: $2.78B – 2.88B; non-GAAP EBITDA: $700M – 730M; non-GAAP Net Income: $300M – 330M.
Previously: Catalent EPS beats by $0.05, beats on revenue (Aug. 27)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.